May 21, 2020 / 9:13 PM / 15 days ago

BRIEF-ECOG-ACRIN Provides Syndax With Results Of Phase 3 E2112 Trial Of Entinostat Plus Exemestane For HR+, HER2- Breast Cancer

May 21 (Reuters) - Syndax Pharmaceuticals Inc:

* ECOG-ACRIN PROVIDES SYNDAX PHARMACEUTICALS WITH RESULTS OF PHASE 3 E2112 TRIAL OF ENTINOSTAT PLUS EXEMESTANE IN PATIENTS WITH HR+, HER2- BREAST CANCER

* SYNDAX - TRIAL DID NOT ACHIEVE PRIMARY ENDPOINT OF DEMONSTRATING A STATISTICALLY SIGNIFICANT OVERALL SURVIVAL BENEFIT OVER HORMONE THERAPY ALONE

* SYNDAX - WILL NOT BE FILING A NEW DRUG APPLICATION WITH FDA FOR METASTATIC BREAST CANCER

* SYNDAX PHARMA - ANTICIPATE PRESENTATION OF ADDITIONAL RESULTS FROM PHASE 1/2 TRIAL OF AXATILIMAB IN PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE IN Q4

* SYNDAX PHARMA - EXPECT TO PRESENT ADDITIONAL DATA FROM AUGMENT-101 TRIAL OF SNDX-5613 IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS LATER IN YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below